Cardiovascular system associated protein kinase 2 (CSAPK-2) antibodies

   
   

The invention provides isolated nucleic acids molecules, designated CSAPK nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CSAPK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CSAPK gene has been introduced or disrupted. The invention still further provides isolated CSAPK proteins, fusion proteins, antigenic peptides and anti-CSAPK antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

De uitvinding verstrekt geïsoleerde nucleic zurenmolecules, aangewezen CSAPK nucleic zuurmolecules, die nieuwe eiwitkinasen coderen. De uitvinding verstrekt antisense nucleic zuurmolecules, recombinante uitdrukkingsvectoren CSAPK nucleic zuurmolecules bevatten, ook gastheercellen waarin de uitdrukkingsvectoren zijn geïntroduceerd, en nonhuman transgenic dieren die waarin een gen CSAPK is geïntroduceerd of onderbroken. De uitvinding verstrekt geïsoleerde proteïnen CSAPK, fusieproteïnen, steeds verder antigenic peptides en antilichamen anti-csapk. Het kenmerkend, worden onderzoeken, en de therapeutische methodes die samenstellingen van de uitvinding gebruiken ook verstrekt.

 
Web www.patentalert.com

< Compositions and methods for drug delivery using amphiphile binding molecules

< Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- .alpha. converting enzyme (TACE)

> 14815, a human kinase family member and uses therefor

> Fiber-reinforced, porous, biodegradable implant device

~ 00113